Introduction {#sec1}
============

Hepatitis usually refers to inflammation of the liver tissue, which may result from both infectious (e.g. viral and bacterial) and noninfectious causes (e.g. alcohol, certain medications, and toxins). Severe liver disease usually contributes to persistent inflammation and necrosis, of which the two primary adverse outcomes are cirrhosis and hepatocellular carcinoma, consequently may cause liver-related death. Here, this article focuses on viral hepatitis because viruses mainly including hepatitis B virus (HBV), and hepatitis C virus (HCV), which have already been proved to be the most common cause of hepatitis worldwide. Furthermore, about a million of patients die from chronic viral hepatitis, most of which occur indirectly from liver scarring or liver cancer \[[@B1]\]. Therefore, early diagnosis of chronic viral hepatitis not only plays a significant role in hepatitis treatment and prevention but also allows for inhibiting disease progression, and decreasing transmission to others to a large extent \[[@B1],[@B2]\].

Nowadays, the laboratory diagnostic tests for hepatitis are mainly based on blood tests, imaging, and liver biopsy \[[@B3]\]. Blood tests include antigens, antibodies, liver-associated enzymes, nucleic acid testing (e.g. hepatitis virus DNA/RNA). Furthermore, hepatic ultrasound, computed tomography, and magnetic resonance imaging are the procedures which can identify steatosis of the liver tissue and nodularity of the liver surface suggestive of cirrhosis. Liver biopsy is still the gold standard for assessing the precise extent and pattern of inflammation and fibrosis of the liver. However, some of these diagnostic approaches are invasive while some fail in early detection of disease due to the limited sensitivity which can only be used in advanced cases \[[@B4]\]. Since the delayed diagnosis may result in poor prognosis, it is necessary to find minimally invasive and cost-effective biomarkers to expand the diagnosis range for liver diseases. Accumulating evidence has witnessed the potential role of circulating miRNAs, as a part of "liquid biopsy", in the diagnostic value for viral hepatitis \[[@B5]\]. miRNAs, a family of highly conserved single-stranded RNA molecules (19--22 nucleotides), have been proved to participated in multiple biological processes mainly including cell cycle, cell proliferation, differentiation, and apoptosis through binding to the complimentary 3′UTR of their target mRNAs and degrading the mRNAs \[[@B6],[@B7]\]. Several research groups have demonstrated that circulating miRNAs, deriving from intracellular miRNAs and secreted out of the cell via exosomes and microvesicles during the process of cell death, can be stably detected in the biofluid like serum, plasma, urine, and cerebrospinal fluid (CSF) from patients making them relatively non-invasive biomarker for infectious diseases \[[@B8]\]. As a major miRNA in liver, miR-122 accounts for approximately 70% of the total liver miRNAs and has been widely reported to suffer from dysregulation in HCV and HBV infection. Besides, the level of miR-122 has been shown to correlate with the severity and stage of infection and helps to evaluate the treatment response \[[@B11]\]. In order to verify the hypothesis and assess the diagnostic value of miR-122 in chronic viral hepatitis, we systematically reviewed the literature and conducted this meta-analysis.

Materials and methods {#sec2}
=====================

Search strategy {#sec2-1}
---------------

In order to retrieve all the articles analyzing the diagnostic value of miR-122 in patients with HBV and/or HCV chronic viral hepatitis, a comprehensive literature search (updated to January 30, 2019) in PubMed, Cochrane library, EMBASE, and CNKI Wanfang and CQVIP databases was performed without language restrictions. The medical subject heading (MeSH) terms ("microRNA-122" or "miRNA-122" or "miR-122" or "hsa-miR-122") and ("diagnostic value" or "diagnoses" or "receiver operating characteristics curve" or "ROC curve" or "sensitivity and specificity") and ("HCV" or "Chronic hepatitis C" or "CHC" or "HBV" or "Chronic hepatitis B" or "CHB") were used to identify all the relevant articles. Besides, we examined the reference lists of review articles and selected papers manually to identify whether there are any other eligible articles.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Studies were considered eligible for inclusion in this meta-analysis had to fulfill the following criteria: (1) evaluate the diagnostic value of miR-122 in patients with HBV and/or HCV-associated chronic viral hepatitis; (2) the patients with HBV-associated chronic viral hepatitis should be positive for HBV surface antigen, positive for HBV DNA, while the diagnosis of HCV-associated chronic viral hepatitis was based on the detection of anti-HCV antibodies and consistent detection of HCV RNA, for at least 6 months; (3) each study involved both experimental and control groups; (4) the miR-122 expression was measured in serum or plasma samples; (5) articles provided sufficient data. Exclusion criteria were as follows: (1) studies with duplicate data; (2) meta-analysis, letters, reviews, case reports; (3) studies without sufficient data or with 20 patients or less.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Two investigators (XHZH and SHQF) are responsible for assessing all the publications. Any disagreements were resolved through discussion with a third reviewer (MW). The following information was extracted from eligible studies: first author's name, year and country of the publication, characteristics of participants (ethnicity, total number of cases and controls, mean/median age), sample types, methods of miR-122 testing, and the data (true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN), sensitivity, and specificity). In addition, the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) was performed to assess the methodological qualities of each included article.

Statistical analysis {#sec2-4}
--------------------

Stata 14.0 (STATA Corp, College Station, TX, U.S.A.) and Meta-DiSc version 1.4 software were used to perform all the statistical analysis and *P*-value less than 0.05 was considered statistically significant. We calculated the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and corresponding 95% confidence intervals (CIs) for the miR-122 studied using the bivariate random-effect regression model \[[@B14]\]. In addition, we determined the sensitivity and specificity of the miRNAs in each study using a bivariate summary receiver operating characteristic (SROC) curve. We calculated the area under the curve (AUC) and the maximum point of intersection between sensitivity and specificity \[[@B15]\]. Moreover, subgroup and sensitivity analysis were carried out to explore potential sources of between-study heterogeneity. And publication bias was assessed by Deeks' funnel plot asymmetry test.

Results {#sec3}
=======

Selection process and characteristics of the eligible studies {#sec3-1}
-------------------------------------------------------------

As presented in [Figure 1](#F1){ref-type="fig"}, a total of 762 articles were initially identified from the primary literature search strategy. 704 articles were left for screening after 65 duplicates were removed through Endnote X7 software. After reviewing their abstracts and titles, 679 articles were removed due to unfit literary forms, research subjects of animal model and irrelevant research topic. Subsequently, the full-texts of the remaining 25 articles were read to assess the eligibility and 10 articles were further excluded. As a result, 15 articles were included in the current meta-analysis \[[@B13],[@B16]\].

![Flowchart of the articles selection process in this meta-analysis](bsr-39-bsr20190900-g1){#F1}

The main characteristics, along with the QUADAS-2 scores of the 15 included articles are summarized in [Table 1](#T1){ref-type="table"}, in an order by the publication year, ranging from 2010 to 2018. In all studies, quantitative real time polymerase chain reaction (qRT-PCR) assays were performed to detect the expression levels of miRNAs in either plasma (*n* = 4) or serum (*n* = 11). Seven articles of these selected studies were conducted in China, while the rest eight articles did research in foreign countries. As for the virus types, six articles focus on HBV-associated chronic viral hepatitis, and nine articles focus on HCV-associated chronic viral hepatitis. In addition, according to the 14-item QUADAS assessment tool, the quality assessments for each included study are presented in [Figure 2](#F2){ref-type="fig"}.

![Overall methodological quality assessments of the included 15 articles based on QUADAS-2 tool](bsr-39-bsr20190900-g2){#F2}

###### The summary characteristics and quality assessment of diagnostic clinical trials included in this meta-analysis

  Included studies   Country       Detection method   Internal reference   Source of the virus   Sample size   Mean age (year)   Sensitivity     Specificity     Specimen   QUADAS-2            
  ------------------ ------------- ------------------ -------------------- --------------------- ------------- ----------------- --------------- --------------- ---------- ---------- -------- ---
  Zhang, 2010        China         SYBR PCR           U6 snRNA             HBV                   83            40                40.2 ± 13.1     39.1 ± 13.4     98%        93%        Plasma   9
  Xu, 2011           China         SYBR PCR           U6 snRNA             HBV                   48            89                NA              NA              80%        96%        Serum    6
  Cermelli, 2011     Egypt         SYBR PCR           miR-238              HCV                   18            19                NA              NA              94%        83%        Serum    7
  Meer, 2012         Netherlands   Taqman PCR         NA                   HCV                   102           25                48.65 ± 10.34   35.3 ± 11.5     95%        92%        Serum    5
  Zhang, 2012        China         SYBR PCR           NA                   HBV                   24            24                37.6 ± 9.0      35.6 ± 10.2     88%        100%       Serum    6
  Kumar, 2014        India         Taqman PCR         U6 snRNA             HCV                   25            25                38.08 ± 10.81   32.53 ± 9.63    92%        84%        Serum    6
  Zhang, 2014        China         SYBR PCR           U6 snRNA             HBV (active)          112           22                NA              NA              86%        63%        Plasma   7
                     China         SYBR PCR           U6 snRNA             HBV (indolent)        19            22                NA              NA              84%        37%        Plasma   
  Zhang, 2015        China         SYBR PCR           U6 snRNA             HCV                   39            29                49.0 ± 14.3     45.0 ± 16.1     92%        79%        Serum    6
  Shaker, 2015       Egypt         SYBR PCR           SNORD68              HCV                   30            55                60.27 ± 8.2     55.88 ± 15.91   90%        100%       Serum    7
  Motawi, 2016       Egypt         SYBR PCR           SNORD68              HCV                   40            30                42.95 ± 11.21   49.9 ± 14.9     93%        100%       Serum    7
  Butt, 2016         Egypt         SYBR PCR           U6 snRNA             HCV (abnormal ALT)    80            60                32.7 ± 9.9      39.2 ± 12.9     87%        97%        Serum    8
                     Egypt         SYBR PCR           U6 snRNA             HCV (normal ALT)      43            60                32.7 ± 9.9      39.2 ± 12.9     65%        93%        Serum    
  Demerdash, 2017    Egypt         SYBR PCR           SNORD68              HCV                   60            60                35.1 ± 6.7      33.9 ± 8.64     80%        88%        Plasma   7
  Wang, 2017         China         Taqman PCR         cel-miR-39           HBV (occult)          119           117               42.30 ± 13.60   45.58 ± 13.08   79%        55%        Serum    9
                     China         Taqman PCR         cel-miR-39           HBV (active)          115           117               42.30 ± 13.60   44.40 ± 13.10   86%        83%        Serum    
  Amr, 2018          Egypt         SYBR PCR           SNORD68              HCV                   50            20                41.5            41.7            72%        85%        Serum    8
  Chen, 2018         China         Taqman PCR         Hsa-miR-25-3p        HBV                   30            30                42.7 ± 10.3     37.6 ± 12.8     80%        83%        Plasma   8

NA, not available.

Diagnostic accuracy of miR-122 in chronic viral hepatitis {#sec3-2}
---------------------------------------------------------

First, significant heterogeneity was found in our meta-analysis, as demonstrated by the results (*I*^2^ = 90.78% for sensitivity and *I*^2^ = 79.18% for specificity, respectively). Thus, the random-effect model was selected for the next calculation. Forest plots of the sensitivity and specificity results are shown in [Figure 3](#F3){ref-type="fig"}. Overall, as shown in [Table 2](#T2){ref-type="table"}, the pooled sensitivity was 0.92 (95%CI: 0.86--0.95), specificity was 0.84 (95% CI: 0.78--0.89), PLR was 5.7 (95%CI: 4.7--8.1), NLR was 0.10 (95%CI: 0.06--0.18), DOR was 57 (95%CI: 25--129), and AUC was 0.93 (95%CI: 0.91--0.95). The SROC curve for the overall results is shown in [Figure 4](#F4){ref-type="fig"}. The above results both suggest that miR-122 can be served as an adjuvant tool for the diagnosis of HBV- and/or HCV-associated chronic viral hepatitis.

![Forest plots of summary sensitivities and specificity of circulating miR-122 in the diagnosis of HBV- and HCV-associated chronic viral hepatitis](bsr-39-bsr20190900-g3){#F3}

![Summary ROC curves for miR-122 in the diagnosis of HBV- and HCV-associated chronic viral hepatitis](bsr-39-bsr20190900-g4){#F4}

###### Summary diagnostic accuracy of circulating miR-122 for HBV and/or HCV

  Analysis            Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)      NLR (95% CI)        DOR (95% CI)    AUC (95% CI)
  ------------------- ---------------------- ---------------------- ----------------- ------------------- --------------- -------------------
  *Virus types*                                                                                                           
  HBV                 0.87 (0.75--0.94)      0.81 (0.75--0.87)      4.7 (3.3--6.7)    0.16 (0.07--0.33)   30 (11--79)     0.88 (0.85--0.91)
  HCV                 0.94 (0.89--0.97)      0.85 (0.78--0.90)      6.6 (4.4--10.0)   0.07 (0.04--0.14)   89 (36--217)    0.95 (0.93--0.97)
  *Sample types*                                                                                                          
  Serum               0.93 (0.86--0.97)      0.86 (0.80--0.90)      6.4 (4.5--9.2)    0.08 (0.04--0.17)   79 (30--207)    0.94 (0.91--0.96)
  Plasma              0.87 (0.72--0.95)      0.79 (0.61--0.90)      4.1 (2.0--8.5)    0.16 (0.07--0.40)   25 (6--109)     0.90 (0.87--0.92)
  *Ethnicity*                                                                                                             
  Chinese             0.87 (0.76--0.93)      0.83 (0.73--0.89)      5.1 (3.0--8.5)    0.16 (0.08--0.31)   32 (11--95)     0.91 (0.88--0.93)
  Non-Chinese         0.95 (0.89--0.97)      0.85 (0.77--0.91)      6.6 (4.4--10.0)   0.06 (0.03--0.13)   100 (36--279)   0.96 (0.94--0.97)
  Overall             0.92 (0.86--0.95)      0.84 (0.78--0.89)      5.7 (4.7--8.1)    0.10 (0.06--0.18)   57 (25--129)    0.93 (0.91--0.95)
  Outliers excluded   0.93 (0.87--0.95)      0.86 (0.82--0.89)      6.6 (4.9--8.9)    0.09 (0.05--0.19)   66 (27--160)    0.94 (0.90--0.96)

Threshold effect and subgroup analysis {#sec3-3}
--------------------------------------

Since threshold effect has been reported to be major cause of between-study heterogeneity and occurs when differences in sensitivities and specificities arise; this effect can be assessed with the spearman correlation coefficient \[[@B30]\]. And a value of −0.298 (*P*=0.229; *P*\>0.05) indicated the absence of the threshold effect in our study. Afterwards, subgroup analyses based on ethnicity, sample types and virus types were also performed. The pooled sensitivity, specificity, PLR, NLR, DOR, and AUC for each subgroup are listed in [Table 2](#T2){ref-type="table"}. As for virus types, the HCV-associated chronic viral hepatitis group showed a higher accuracy than HBV-associated chronic viral hepatitis group with sensitivity of 0.94 versus 0.87, specificity of 0.85 versus 0.81, PLR of 6.6 versus 4.7, NLR of 0.07 versus 0.16, DOR of 89 versus 30 and AUC of 0.95 versus 0.88, respectively. Furthermore, a comparison of miR-122 expression profile in serum and plasma showed that the sensitivity (0.93 versus 0.87), specificity (0.86 versus 0.79), and AUC (0.94 versus 0.90) were higher in serum-based test than in plasma, providing additional evidence for the use of serum as a better matrix for diagnostic profiling of miR-122 in patients with HBV- and/or HCV-associated chronic viral hepatitis. Afterwards, the analysis based on ethnicity demonstrated the non-Chinese populations yield a better diagnosis accuracy than their Chinese counterparts. Specifically, for the non-Chinese population group, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.95, 0.85, 6.6, 0.06, 100, and 0.96, while the results for the Chinese population group were 0.97, 0.83, 5.1, 0.16, 32, and 0.91, respectively.

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

As shown in [Figure 5](#F5){ref-type="fig"}A,B, the results of goodness of fit and bivariate normality analysis suggested that the random-effect model was suitable for subsequent calculation of the pooled estimates. Afterwards, influence analysis and outlier detection ([Figure 5](#F5){ref-type="fig"}C,D) identified two outlier researches. After excluding these outliers, sensitivity increased from 0.92 to 0.93, specificity increased from 0.84 to 0.86, PLR increased from 5.7 to 6.6, NLR decreased from 0.10 to 0.09, DOR increased from 57 to 66, and AUC increased from 0.93 to 0.94. In addition, heterogeneity increased from 90.78% to 91.19% for sensitivity and from 79.18% to 62.02% for specificity. Furthermore, Deeks' funnel plot asymmetry test was carried out to explore the potential publication bias of the included studies. As demonstrated in [Figure 6](#F6){ref-type="fig"}, an obtained *P* value of 0.29 indicated the absence of publication bias in this meta-analysis.

![Sensitivity analysis: graphical depiction of goodness of fit and bivariate normality analysis (**A,B**), influence and outlier detection analysis (**C,D**), respectively](bsr-39-bsr20190900-g5){#F5}

![Deeks' funnel plot asymmetry test for the assessment of potential publication bias](bsr-39-bsr20190900-g6){#F6}

Discussion {#sec4}
==========

Though significant progress has been occurred in diagnostic techniques over the years, the accurate and convenient diagnosis of HBV- and/or HCV-associated chronic viral hepatitis remains a clinical challenge. Subsequently, the application of miRNAs, which can control gene expression in multiple biological processes including growth, cell proliferation, differentiation, apoptosis, and carcinogenesis through RNA interference (RNAi) \[[@B31],[@B32]\], has gained much attention. As a part of miRNAs, miR-122 has already been demonstrated to be the most frequent miRNA in adult human liver accounting up to 70% of the total hepatic miRNAs, and a central player in liver development, differentiation, and homeostasis as well as in metabolic functions \[[@B33]\]. There is a great deal of researches into the use of miR-122 as a biomarker for HBV and HCV. In the aspect of HBV regulation, Chen et al. \[[@B34]\] have demonstrated that miR­122 can bind to the highly conserved region of a bicistronic mRNA called HBV pregenomic RNA, which reported to encode the HBV polymerase and core protein, thereby ultimately leading to inhibition of HBV gene expression and replication. Furthermore, it has also been confirmed that increase in miR­122 can attenuated the replication of HBV by regulating cyclin G(1) -modulated P53 activity \[[@B35]\]. As for the aspect of HCV regulation, liver-specific miR­122 can stabilize HCV viral RNA through a process involving protecting highly conserved 5′ untranslated region the HCV genome from degradation by the host exonuclease, Xrn­1 or from host innate immune responses \[[@B36]\]. A phase 2a study has shown that miravirsen, an antisense oligonucleotide, exhibited remarkable prolonged dose-dependent reductions in HCV RNA levels in patients with chronic HCV genotype 1 infection \[[@B40]\]. All the above researches both suggest that miR­122 is a significant regulator of HBV and HCV replication by either directly affecting viral RNA or modulating host gene expression.

However, due to the different study designs and study subjects, some studies dispute its diagnostic efficacy \[[@B41]\]. Thus, the present study was carried out to summarize the results of individual studies. As the present results show, circulating miR-122 achieved a pooled sensitivity of 0.92, specificity of 0.84, and AUC of 0.93, indicating an overall moderate test performance for the diagnosis of HBV- and HCV-associated chronic viral hepatitis. Furthermore, the PLR value of 5.7 suggested that HBV- and HCV-associated chronic viral hepatitis patients had an almost six-fold higher chance of being miR-122 test positive than other individuals without the disease, and a NLR value of 0.1 implied that in a negative result from the miR-122 test, only 10% is likely to be false-negative. Obviously, the DOR value, which combines the strengths of both sensitivity and specificity, was 57 in our meta-analysis, indicating a high level of discriminating accuracy for clinical practice \[[@B42]\].

Furthermore, to explore the potential sources of heterogeneity, subgroup analysis based on virus types, sample types and ethnicity were subsequently performed. The results of subgroup analysis based on virus types suggest that miRNA-122 yielded an overall higher diagnostic accuracy in HCV-associated chronic viral hepatitis patients with a sensitivity of 0.94, specificity of 0.85, PLR of 6.6, NLR of 0.07, DOR of 89, and AUC of 0.95. Besides, with regard to sample types, miRNA expression profiles have been reported to be considerably affected by the coagulation process in the blood \[[@B43]\]. In our study, serum turned out to be a better matrix for diagnostic profiling of miR-122 in HBV- and HCV-associated chronic viral hepatitis than plasma: the pooled sensitivity was 0.93 versus 0.87, specificity was 0.86 versus 0.79, PLR was 6.4 versus 4.1, NLR was 0.08 versus 0.16, DOR was 79 versus 25, and AUC was 0.94 versus 0.90. However, as only four studies were included in the plasma specimen group, thus large-scale prospective researches are still needed to consolidate the results. In the subgroup analysis based on ethnicity, we found compared with Chinese populations, miR-122 assay may be more accurate in non-Chinese populations, with the DOR value hiked from 32 to 100, and AUC increased from 0.91 to 0.96.

Admittedly, heterogeneity still exists when interpreting the results of any meta-analysis. In our study, heterogeneity does not come from the threshold effect. However, in the sensitivity analysis, after excluding the outlier, the overall pooled sensitivity, sensitivity, PLR, DOR, and AUC all increased while NLR decreased suggesting that the outlier is probably a source of heterogeneity. In addition, as the *P* value of *I*^2^ for the overall study altered inconspicuously, substantial heterogeneity from non-threshold effect still exists among studies to some extent. Although we have made every effort to avoid bias during the process of our study, there were still some limitations in this meta-analysis. In the first place, several valuable studies may be missed in spite of the comprehensive search strategy during our literature search. What's more, diagnostic performance maybe affected as the majority of healthy people were randomly selected as controls and were not blind designed.

Conclusions {#sec5}
===========

Taken together, for the first time, our meta-analysis focuses on the diagnostic performance of circulating miRNA-122 in HBV- and/or HCV-associated chronic viral hepatitis detection, and it is concluded that circulating miRNA-122 has a relatively high diagnostic value for chronic viral hepatitis detection, especially in patients of HCV-associated chronic viral hepatitis. However, in the future, well-designed, large-scale and accurate researches are still needed to consolidate the results of this meta-analysis in clinical practice. The ultimate purpose is to combine clinical variables with those available in public databases to open avenues for prospective trials of a non-invasive diagnostic test for enhancing the early detection of patients with chronic viral hepatitis.
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